Emerging studies indicate that LRP2 mutations may not always be direct drivers of oncogenesis but could function as passenger mutations within the genomic landscape of highly mutated tumors—this perspective aligns with findings linking LRP2 mutations to increased TMB and T cell density, which influence the tumor microenvironment and response to immunotherapy (78, 79). The gene discussed is LRP2; the disease is neoplasm.